[A comparison of the time of in vivo resistance development of tubercle bacilli to rifampicin, kanamycin, ethionamide, lividomycin, and enviomycin (tuberactinomycin-N) in patients with chronic cavitary tuberculosis (author's transl)].
D000995:Antitubercular Agents / Q000494:pharmacology / Q000627:therapeutic use*; D004352:Drug Resistance, Microbial; D004776:Enviomycin / Q000627:therapeutic use; D005000:Ethionamide / Q000627:therapeutic use; D006801:Humans; D007612:Kanamycin / Q000627:therapeutic use; D009169:Mycobacterium tuberculosis / Q000187:drug effects*; D010303:Paromomycin / Q000031:analogs & derivatives / Q000627:therapeutic use; D012293:Rifampin / Q000627:therapeutic use; D013997:Time Factors; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
D000995:Antitubercular Agents; D007612:Kanamycin; D010303:Paromomycin; D005000:Ethionamide; D012293:Rifampin; D004776:Enviomycin